BioAtla (BCAB) Projected to Post Earnings on Thursday

BioAtla (NASDAQ:BCAB) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 4:00 PM ET.

BioAtla Stock Performance

Shares of BCAB stock opened at $0.17 on Tuesday. BioAtla has a 52-week low of $0.13 and a 52-week high of $1.43. The stock has a market cap of $10.79 million, a price-to-earnings ratio of -0.15 and a beta of 1.08. The firm’s 50-day moving average is $0.22 and its 200-day moving average is $0.55.

Institutional Trading of BioAtla

Hedge funds have recently modified their holdings of the stock. Woodline Partners LP bought a new stake in shares of BioAtla during the 1st quarter worth about $26,000. ADAR1 Capital Management LLC bought a new position in BioAtla in the 4th quarter valued at about $104,000. Susquehanna International Group LLP raised its holdings in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares during the period. Jane Street Group LLC lifted its position in BioAtla by 55.4% during the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in BioAtla during the third quarter worth approximately $235,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on BCAB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a research report on Friday, January 9th. Rodman & Renshaw assumed coverage on BioAtla in a research report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective for the company. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $4.00.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.